Memory Management
From Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record — five realities of the peptide cognition frontier, and the regulatory minefield around them.
An evidence-based exploration of memory-management peptides including Dihexa, Semax, Selank, P21, and Cerebrolysin. We examine synaptogenic potency claims alongside oncogenic risk, the FDA's 2024 compounding ban, and where clinical evidence ends and biohacking speculation begins.
memory-managementpeptidesdihexasemaxselank+7